StockData
BlossomHill Therapeutics, Inc. logo

BlossomHill Therapeutics, Inc. (BLSM) shareholders

BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.13+1.48 (+10.84%)

Close on Nov 17, 2026Market cap $38.56MP/E –Yield –

Ownership

Who owns BlossomHill Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
7 buys · 0 sales
Net bought $25.18M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Chen Bihua
Joint filing with Cormorant Asset Management, LP (11.79%)
3,615,36211.80%13D (active)Aug 6, 2026
OrbiMed Capital GP VIII LLC
Joint filing with Orbimed Advisors LLC (8.90%)
2,714,2798.90%13D (active)Aug 10, 2026
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (5.90%), Joseph Edelman (5.90%)
1,808,5335.90%13G (passive)Aug 7, 2026
Vivo Innovation Fund II Holdings, L.P.
Joint filing with Vivo Innovation II, LLC (5.50%)
1,681,2405.50%13G (passive)Aug 10, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jingrong Jean CuiPresident and CEO, Director, 10% owner3,973,13812.50%Aug 10, 2026
Yishan LiExecutive Chairman, Director, 10% owner3,859,70312.14%Aug 10, 2026
Vincent Paul LiptakGeneral Counsel134,0990.42%Aug 10, 2026
Jason A. KeyesChief Financial Officer7000.00%Aug 10, 2026
Geoffrey Raymond OxnardChief Medical Officer17,7850.06%Aug 10, 2026
Advisors Llc OrbimedDirector––Aug 12, 2026
Capital GP VIII LLC OrbiMedDirector2,714,2798.54%Aug 12, 2026
Carl L. GordonDirector2,714,2798.54%Aug 12, 2026
John P. SchmidDirector6,0000.02%Aug 10, 2026
Sundeep AgrawalDirector578,5241.82%Aug 10, 2026
Bihua ChenDirector, 10% owner––Aug 10, 2026
Sheila GujrathiDirector90,1600.28%Aug 6, 2026
Private Healthcare Fund III LP Cormorant10% owner––Aug 10, 2026
Cormorant Asset Management, LP10% owner––Aug 10, 2026
Cormorant Global Healthcare Master Fund, LP10% owner––Aug 10, 2026
Private Healthcare Fund V. LP Cormorant10% owner––Aug 10, 2026
Cormorant Private Healthcare Fund VI, LP10% owner3,301,53410.39%Aug 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Carl L. Gordon
Director
Aug 10, 2026Buy+625,000$16.00$10.00M2,714,279
Carl L. Gordon
Director
Aug 10, 2026Conversion+1,039,996––1,039,996
Carl L. Gordon
Director
Aug 10, 2026Conversion+1,049,283––2,089,279
Capital GP VIII LLC OrbiMed
Director
Aug 10, 2026Buy+625,000$16.00$10.00M2,714,279
Capital GP VIII LLC OrbiMed
Director
Aug 10, 2026Conversion+1,049,283––2,089,279
Capital GP VIII LLC OrbiMed
Director
Aug 10, 2026Conversion+1,039,996––1,039,996
John P. Schmid
Director
Aug 10, 2026Buy+6,000$16.00$96.00K6,000
Yishan Li
Executive Chairman, Director, 10% owner
Aug 10, 2026Conversion+1,600,682––1,600,682
Yishan Li
Executive Chairman, Director, 10% owner
Aug 10, 2026Conversion+124,779––124,779
Yishan Li
Executive Chairman, Director, 10% owner
Aug 10, 2026Conversion+113,435––1,714,117
Jason A. Keyes
Chief Financial Officer
Aug 10, 2026Buy+700$16.00$11.20K700
Jingrong Jean Cui
President and CEO, Director, 10% owner
Aug 10, 2026Conversion+113,435––1,714,117
Jingrong Jean Cui
President and CEO, Director, 10% owner
Aug 10, 2026Conversion+124,779––124,779
Jingrong Jean Cui
President and CEO, Director, 10% owner
Aug 10, 2026Conversion+1,600,682––1,600,682
Cormorant Private Healthcare Fund VI, LP
10% owner
Aug 10, 2026Conversion+1,701,541––3,301,534
Cormorant Private Healthcare Fund VI, LP
10% owner
Aug 10, 2026Conversion+1,599,993––1,599,993
Cormorant Private Healthcare Fund VI, LP
10% owner
Aug 10, 2026Buy+312,500$16.00$5.00M3,614,034
Sundeep Agrawal
Director
Aug 10, 2026Conversion+578,524––578,524
Vincent Paul Liptak
General Counsel
Aug 10, 2026Conversion+22,687––22,687
Vincent Paul Liptak
General Counsel
Aug 10, 2026Buy+2,200$16.00$35.20K111,412
Vincent Paul Liptak
General Counsel
Aug 7, 2026Buy+2,500$15.80$39.50K109,212

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
23.15%
1M shares short
Days to cover
4.7
At 0M shares a day
Change since last report
+21.7%
From 0M shares
Short volume, 20 days
62.4%
Of volume reported to FINRA

Shares sold short, last 3 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BlossomHill Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,898 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?